Moderna shares are down 7% following headlines that its virus vaccine trial has been delayed…
A 30,000-patient trial of Moderna’s coronavirus vaccine candidate, expected to start next week, has been delayed, investigators say, while stressing a start later in the month is still possible. https://t.co/w2uzdP6FGU
— STAT (@statnews) July 2, 2020
MRNA back to its lowest since May…
Where’s Dr. Fauci to tell us how great it is still?
$MRNA trial delay all but assures they will be left in the dust by the nearly hundred other vaccine candidates IMO
— Quoth the Raven (@QTRResearch) July 2, 2020
Interestingly, this headline hit shortly after WHO’s Chief Scientist Soumya Swaminathan said that more analysis was need to understand the efficacy of Gilead’s Remdesivir.
Source: ZERO HEDGE